• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, August 22, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

More evidence shows natural plant compound may reduce mental effects of aging

Bioengineer by Bioengineer
July 10, 2017
in Health
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: Salk Institute

LA JOLLA–(July 10, 2017) Salk scientists have found further evidence that a natural compound in strawberries reduces cognitive deficits and inflammation associated with aging in mice. The work, which appeared in the Journals of Gerontology Series A in June 2017, builds on the team's previous research into the antioxidant fisetin, finding it could help treat age-related mental decline and conditions like Alzheimer's or stroke.

"Companies have put fisetin into various health products but there hasn't been enough serious testing of the compound," says Pamela Maher, a senior staff scientist in Salk's Cellular Neurobiology Laboratory and senior author of the paper. "Based on our ongoing work, we think fisetin might be helpful as a preventative for many age-associated neurodegenerative diseases, not just Alzheimer's, and we'd like to encourage more rigorous study of it."

Maher, who works in the lab of David Schubert, the head of Salk's Cellular Neurobiology Lab, has been studying fisetin for over a decade. Previous research by the lab found that fisetin reduced memory loss related to Alzheimer's in mice genetically modified to develop the disease. But that study focused on genetic (familial) AD, which accounts for only 1 to 3 percent of cases. By far the bigger risk factor for developing what is termed sporadic AD, as well as other neurodegenerative disorders, is simply age. For the current inquiry, Maher turned to a strain of laboratory mice that age prematurely to better study sporadic AD. By 10 months of age, these mice typically show signs of physical and cognitive decline not seen in normal mice until two years of age.

The Salk team fed the 3-month-old prematurely aging mice a daily dose of fisetin with their food for 7 months. Another group of the prematurely aging mice was fed the same food without fisetin. During the study period, mice took various activity and memory tests. The team also examined levels of specific proteins in the mice related to brain function, responses to stress and inflammation.

"At 10 months, the differences between these two groups were striking," says Maher. Mice not treated with fisetin had difficulties with all the cognitive tests as well as elevated markers of stress and inflammation. Brain cells called astrocytes and microglia, which are normally anti-inflammatory, were now driving rampant inflammation. Mice treated with fisetin, on the other hand, were not noticeably different in behavior, cognitive ability or inflammatory markers at 10 months than a group of untreated 3-month-old mice with the same condition. Additionally, the team found no evidence of acute toxicity in the fisetin-treated mice, even at high doses of the compound.

"Mice are not people, of course," says Maher, "But there are enough similarities that we think fisetin warrants a closer look, not only for potentially treating sporadic AD but also for reducing some of the cognitive effects associated with aging, generally."

Next, Maher hopes to partner with another group or company in order to conduct clinical trials of fisetin with human subjects.

###

Other authors included: Antonio Currais, Catherine Farrokhi and Richard Dargusch of Salk and Aaron Armando and Oswald Quehenberger of the University of California, San Diego.

The work was funded by the Alzheimer's Association, the Burns Foundation and the National Institutes of Health.

About the Salk Institute for Biological Studies:

Every cure has a starting point. The Salk Institute embodies Jonas Salk's mission to dare to make dreams into reality. Its internationally renowned and award-winning scientists explore the very foundations of life, seeking new understandings in neuroscience, genetics, immunology, plant biology and more. The Institute is an independent nonprofit organization and architectural landmark: small by choice, intimate by nature and fearless in the face of any challenge. Be it cancer or Alzheimer's, aging or diabetes, Salk is where cures begin. Learn more at: salk.edu.

Media Contact

Salk Communications
[email protected]
858-453-4100
@salkinstitute

Salk Institute for Biological Studies

Original Source

https://www.salk.edu/news-release/evidence-shows-natural-plant-compound-may-reduce-mental-effects-aging/

Share12Tweet8Share2ShareShareShare2

Related Posts

Real-world study examines psychotic complications of subcutaneous foslevodopa/foscarbidopa infusions in 198 patients

Real-world study examines psychotic complications of subcutaneous foslevodopa/foscarbidopa infusions in 198 patients

August 22, 2026

Blood-flow signals from liver vessels direct region-specific liver function through Wnt pathways

August 22, 2026

Proteomics Links Environmental and Genetic Parkinson’s Models to Purine Metabolism

August 22, 2026

Wearable Devices Track Activity Rhythms to Reveal Biological Aging Over Time

August 22, 2026
Please login to join discussion

POPULAR NEWS

  • Real-world study examines psychotic complications of subcutaneous foslevodopa/foscarbidopa infusions in 198 patients

    29 shares
    Share 12 Tweet 7
  • Blood-flow signals from liver vessels direct region-specific liver function through Wnt pathways

    29 shares
    Share 12 Tweet 7
  • Ge/SiGe Quantum-Well Photodetectors Integrated with SiN Waveguides on 200-mm Silicon Wafers

    29 shares
    Share 12 Tweet 7
  • Consensus Roadmap Guides Clinical Trials for Rare Childhood CNS Tumors

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Real-world study examines psychotic complications of subcutaneous foslevodopa/foscarbidopa infusions in 198 patients

Blood-flow signals from liver vessels direct region-specific liver function through Wnt pathways

Ge/SiGe Quantum-Well Photodetectors Integrated with SiN Waveguides on 200-mm Silicon Wafers

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 85 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.